India Set to Dominate Global Pharma Sector with Innovative Strategies
Synopsis
India is on the brink of becoming a leader in the global pharmaceutical market, emphasizing biologics and biosimilars, thanks to significant government initiatives and a focus on innovation. Health Minister JP Nadda outlines the country's robust capabilities and future opportunities.
Key Takeaways
India is focusing on biologics and biosimilars to lead the pharmaceutical sector.
The Biopharma Shakti Initiative has a substantial financial backing of Rs 10,000 crore.
Innovative drugs make up 87% of the global pharmaceutical market value.
India accounts for 20% of global generic medicines and fulfills 70% of vaccine demands.
The biosimilars market is expected to grow to $75 billion by 2030.
New Delhi, April 13 (NationPress) India is ready to take the lead in the international pharmaceutical sector, driven by a commitment to biologics, biosimilars, and specialty drugs, as stated by Health Minister JP Nadda on Monday.
The minister emphasized the government's recent launch of the Biopharma Shakti Initiative, backed by an investment of Rs 10,000 crore, aimed at enhancing biopharmaceutical innovation capabilities, fostering creativity, and bolstering research infrastructure.
Union Minister of State for Health and Family Welfare, Anupriya Patel, stressed the necessity for the industry to ramp up its focus on innovation, noting that innovative medications constitute nearly 87 percent of the total value of the global pharmaceutical market.
Nadda also mentioned supportive initiatives including the PRIP scheme, which promotes research in pharmaceuticals and medical technology, Production-Linked Incentive programs, and the Pradhan Mantri Bharatiya Jan Aushadhi Pariyojana, all of which aim to enhance domestic production, ensure affordable access to medications, and encourage collaboration between industry and academia for the development of groundbreaking therapies.
He added that the 'India Pharma 2026' event serves as a crucial platform for fostering discussions, partnerships, and a future-oriented roadmap for the pharmaceutical sector.
Patel remarked that India is transitioning significantly from being a global leader in generics to an emerging hub for biopharma innovation.
The nation currently accounts for approximately 20 percent of global generic medicines and fulfills around 70 percent of worldwide vaccine demands, showcasing its strong manufacturing capabilities, she highlighted.
Focusing on future prospects, Patel pointed out that the demand for biologics and biosimilars is rapidly increasing, with projections indicating that the biosimilars market could reach $75 billion by 2030.
She emphasized the importance of nurturing human capital through esteemed institutions like NIPERs and IITs to support advanced research and innovation.
The ministers participated in the 9th edition of 'India Pharma 2026', a two-day conference organized by the Department of Pharmaceuticals (DoP) in collaboration with FICCI and the Indian Pharmaceutical Alliance (IPA). This event unites key players from the global pharmaceutical and healthcare landscape, emphasizing innovation, self-reliance, and global leadership.
aar/na
Point of View
India's commitment to leading the pharmaceutical sector through innovative approaches is commendable. The government's emphasis on biologics and biosimilars signifies a strategic shift towards advanced healthcare solutions, positioning the nation as a global player in pharmaceuticals while ensuring accessibility and affordability.
NationPress
1 May 2026
Frequently Asked Questions
What is the Biopharma Shakti Initiative?
The Biopharma Shakti Initiative is a government program launched with an investment of Rs 10,000 crore aimed at enhancing India's capabilities in biopharmaceutical innovation and research.
How much of the global pharmaceutical market value do innovative drugs account for?
Innovative drugs account for nearly 87 percent of the total value of the global pharmaceutical market.
What percentage of global generic medicines does India produce?
India produces approximately 20 percent of the world's generic medicines.
What is the projected market size of biosimilars by 2030?
The biosimilars market is projected to reach $75 billion by 2030.
What role do institutions like NIPERs and IITs play in this initiative?
Institutions like NIPERs and IITs are essential for nurturing human capital and supporting advanced research and innovation in the pharmaceutical sector.
